Meeting
2015 ASCO Annual Meeting
Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer.
Authors
Suleiman Alfred Massarweh
University of Kentucky, Lexington, KY
Suleiman Alfred Massarweh , Juliann Chmielecki , James Sun , Rachel Lauren Stewart , Emily Van Meter Dressler , Vera Kadamyan , Mara D. Chambers , Craig Horbinski , Murtaza Mehdi , Esther P. Black , Edward H. Romond
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 532)
DOI
10.1200/jco.2015.33.15_suppl.532
Abstract #
532
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway.
First Author: Esther P. Black
Poster
2023 ASCO Genitourinary Cancers Symposium
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
First Author: Adrish Sen
First Author: Cristina I. Truica